-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Marnetegragene Autotemcel in Leukocyte Disorders (White Blood Cell Disorders)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Marnetegragene Autotemcel in Leukocyte Disorders (White Blood Cell Disorders) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Marnetegragene Autotemcel in Leukocyte Disorders (White...
-
Sector Analysis
NewInternet from Sky – Can LEO Satellites Transform the Future of Connectivity? (Vol. 2)
LEO Satellites - Internet from Sky Report Overview The surge in low earth orbit (LEO) satellite projects indicates a global trend toward diversifying internet coverage. This trend focuses on bridging the digital divide and enhancing real-time data transmission for various sectors, including aerospace and defense. LEOs provide a competitive edge due to their lower latency, and their increasing deployment signifies a pivotal shift toward a more connected future. LEOs are more secure than terrestrial networks as communication happens in space...
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Volrustomig
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Volrustomig report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MET-5 in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MET-5 in Hypertriglyceridemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MET-5 in Hypertriglyceridemia Drug Details: MET-5 is under development for the treatment of...
-
Product Insights
NewCardiomyopathy – Drugs In Development, 2024
Empower your strategies with our Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Cardiomyopathy a disease of the heart muscle, where the walls of the heart chambers have become stretched, thickened or stiff. This affects the heart's ability to pump blood around the body. Most types of cardiomyopathy are inherited. It can also be caused by other conditions, or risk factors, but for some people the cause is unknown. Cardiomyopathy can affect people of all ages...
-
Product Insights
NewLeukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024
Empower your strategies with our Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2024 report and make more profitable business decisions. Leukocyte disorders, also known as white blood cell disorders, encompass a range of conditions that involve abnormalities in the production, function, or levels of white blood cells (leukocytes). White blood cells play a crucial role in the immune system, defending the body against infections, diseases, and foreign invaders. The Leukocyte Disorders (White Blood Cell Disorders) drugs in development...
-
Product Insights
NewDilated Cardiomyopathy – Drugs In Development, 2024
Empower your strategies with our Dilated Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include fatigue and weakness, shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention, and swelling (edema) in legs, ankles, and...
-
Product Insights
NewFanconi Anemia – Drugs In Development, 2024
Empower your strategies with our Fanconi Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Fanconi anemia, or FA, is a rare, inherited blood disorder that leads to bone marrow failure. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment...